Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can AI-Controlled heat ease chronic pelvic pain?

NCT ID NCT07791277

Symptom relief Sponsor: Jiangxi Women and Children's Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This trial compares two non-drug treatments for myofascial pelvic pain syndrome in women: precise AI-controlled radiofrequency therapy versus biofeedback combined with electrical stimulation. Researchers will randomly assign 70 women to one of the two treatments and measure changes in pain, pelvic floor muscle strength, sexual function, and anxiety. The goal is to see which approach offers better relief and improvement in quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Precision AI temperature-controlled radiofrequency therapy delivered via an intravaginal probe, compared with biofeedback combined with electrical stimulation
What this could lead to
If it works, this could point toward a more effective, non-drug treatment for chronic pelvic pain in women, potentially easing pain and improving sexual function and anxiety.
What could go wrong
This is a small, early comparative study with 70 participants, so results may not apply broadly. The radiofrequency device heats pelvic tissue, which carries risks like burns or discomfort, and the AI control is new.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

70 people

The number who actually took part.

Started

May 2026

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients with a confirmed diagnosis of MPPS * Have signed the informed consent form * Aged over 18 years old and sexually active Exclusion Criteria: * Concurrent vaginitis; * Pregnancy, pre-pregnancy, or within 6 months postpartum * Abnormal vaginal bleeding * Severe systemic conditions * Internal metallic implants * Skin lesions in the treatment region * Organic pelvic pathologies * Systemic or neuropathic pain syndromes * Concurrent use of pharmacological therapy * intolerance to the current treatment protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myofascial pain dysfunction syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fibromyalgia myofascial pain syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myofascial pain dysfunction syndrome Myofascial pelvic pain syndrome

Contacts and locations

Locations

  • Jiangxi Maternal and Child Health Hospital

    Nanchang, Jiangxi, 330000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.